Corcept rises after ovarian cancer drug shows positive results in mid-stage study

** Corcept Therapeutics CORT.O shares gain 3% to $87.23 premarket

** Biotech says its ovarian cancer drug Lifyorli, combined with chemotherapy drug nab-paclitaxel and bevacizumab, showed positive results in patients with platinum-resistant ovarian cancer

** Adds that regimen delivered median progression-free survival of 7.2 months, an objective response rate of 59% in 95-patient study

** Patients who had not previously received bevacizumab showed better results, with median progression-free survival of 8.1 months and an objective response rate of 66% - CORT

** Says 88% patients were alive at six months; median overall survival had not been reached at the primary analysis

** As of last close, stock up ~147% YTD